Abstract
A possible involvement of human herpesvirus 6 High titres of anti-HHV-6 antibodies and the presence of HHV-6 genomic sequences are frequently associated with immune disorders. '7 Up to now, a large number of viral agents have been investigated in multiple sclerosis (MS),18 but not HHV-6. We were interested in studying the HHV-6 infection in MS patients because of its biological characteristics, including its strong CD4 + T cell tropism, synergic action with other viruses, and the occurrence of the infection early in human life with persistence in latent form in the adults.
Materials and methods
We tested for anti-HHV-6 antibody by indirect immunofluorescence analysis (IFA) the serum and CSF samples collected from 126 MS patients (47 men and 79 women, mean age 35 years, range 13-70). The sera from 500 healthy, HIV-negative, blood donors (250 men and 250 women, mean age 44 years) were also examined to establish a control value for a normal population. Indirect IFA was performed on HHV-6 infected HSB-2 cells as described by Ablashi et centa and from HSB-2 cells infected by HHV-6, strain GS. The pZVH14 sequence of this case compared with the same sequence of GS strain, showed the same restriction fragment length polymorphism (RLFP), with all the enzymes used. The PCR assay performed on the DNAs of 24 normal subjects showed only one positive case. In this case the signal was very faint and the Southern analysis was negative, suggesting that the number of copies of HHV-6 sequences detected is much lower than in the positive MS patient. Both the two PCR positive cases were negative for serum anti-HHV-6 antibody at IFA analysis.
Discussion
Our results on anti-HHV-6 antibody titres in the blood donors group are in good agreement with published data,7-9 and suggest that HHV-6 infection is widespread in our region, as well as in a number of other countries. Moreover, the use of 1:40 dilution makes unlikely a non-specific reaction, while a possible immunological crossreactivity between HHV-6 and other herpesviruses has been ruled out by several authors. ' 8 9 To explain the high anti-HHV-6 antibody titres in MS, it may be speculated that in this disease the impairment of the cellular immune response may lead to the reactivation of an HHV-6 latent infection. This reactivation may in turn determine an increase of anti-HHV-6 antibody titres. This explanation cannot be ruled out; however, it seems unlikely in view of our PCR data, since we found HHV-6 sequences in the PBMC DNA of only one out of 31 MS patients, in spite of the known lymphotropism of this virus. In the absence of a satisfactory explanation we can only say that the immune system in MS is activated against HHV-6, in the absence of detectable viral sequences.
In nine MS patients anti-HHV-6 IgG were present also in the CSF. Because only two out of nine MS patients with CSF anti-HHV-6 antibodies show BBB damage, we suggest that in these patients the immune stimulation leads to the synthesis of these antibodies by intrathecal lymphocyte clones, as confirmed by the high CSF IgG index frequently found. Within the limits of sensitivity of our PCR assay, two positive cases were found: one MS patient and one healthy control, both negative for HHV-6 antibody. We have no explanation for this discrepancy which is typically associated with latent infection22 or could be due to immune disregulation. In spite of the use of two different sets of primers, the molecular tests performed do not allow us to establish with absolute certainty the presence in PBMCs of complete HHV-6 genomes. However, the amplified sequences are HHV-6 specific, because the primers used do not cross hybridise with normal human DNA or with other herpesvirus DNAs.
The positive MS patient showed an unexpectedly high number of copies of HHV-6 sequences, so that these sequences were easily detectable by a standard Southern analysis, contrary to the normal positive control. Only an in situ hybridisation assay would allow us to establish if there are few cells with a high number of HHV-6 sequences or several cells carrying few HHV-6 molecules. The faint positivity in the PCR assay of the normal positive subject suggests that in this case only a rare cell in the peripheral blood is infected with few copies of HHV-6. The difference between the two positive cases could be related to the immune impairment of MS, which would make possible the expansion of a latent infection not allowed by an intact immune system. Otherwise, the immune impairment of the disease could be viewed as a consequence rather than as the origin of the high-viral titres.
Since HHV-6 is able to infect other cells beside T lymphocytes, a reason for these results may be that the virus remains latent in cells other than PBMCs, perhaps in the oligodendrocytes. Lastly, it is also impossible to exclude that variant HHV-6, not well hybridising to our primers, can be present in the PBMCs examined.
At present, we cannot draw any conclusion in favour of or against a possible role of HHV-6 in the pathogenesis of some MS cases. Moreover, the possibility that HHV-6 proteins may cause the transactivation of other cellular or viral genes contributing in this way to the immune derangement of MS cannot be ruled out. 23 We emphasise that further refining of antibody test systems, experience with larger numbers of subjects, and careful prospective and molecular studies are necessary before conclusions can be made regarding the relations between the MS and HHV-6 infection.
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